GlassScriptPhysician profile
Kelly Suchar
NPI 1831733252
$3,095.57
in general payments reported to CMS, 2019-2025
18 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $437 · 2023: $1,607 · 2024: $315 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.53 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $507.66 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $490.31 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $331.44 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.57 | 2022-2025 | Caplyta |
| Lundbeck LLC | $194.90 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $139.82 | 2022-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $135.46 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $124.27 | 2022-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $99.55 | 2025 | Fanapt, Hetlioz |
| Corium, LLC | $91.73 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $47.46 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $37.65 | 2022 | |
| Tris Pharma INC | $37.16 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $36.10 | 2023 | Sertraline Hcl, Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $20.32 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $18.51 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Suchar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.